Highlight
– Targeted screening using N-terminal pro-B-type natriuretic peptide (NT-proBNP) identifies a large proportion of previously unrecognized heart failure (HF) cases in high-risk diabetic patients.
– Most newly diagnosed HF cases in this population are heart failure with preserved ejection fraction (HFpEF).
– Screening led to increased use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), disease-modifying therapy with established cardiovascular benefits.
– The number needed to screen was only five to detect one new HF case, highlighting the clinical impact and feasibility of such strategies.
